Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 2 Mar 2021 |
| Orion Corporation: Managers’ transactions – Olli Huotari | 2 Mar 2021 |
| Orion Corporation: Managers’ transactions – Jari Karlson | 2 Mar 2021 |
| Orion Corporation: Managers’ transactions – Liisa Hurme | 2 Mar 2021 |
| Orion Corporation: Managers’ transactions – Satu Ahomäki | 2 Mar 2021 |